Journal
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
Volume 23, Issue 2, Pages 111-118Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/S1773-2247(13)50018-9
Keywords
Inulin; Doxorubicin; Drug resistance; Conjugate; Cytotoxicity
Categories
Funding
- NIH/NCI Center for Oncophysics [CTOPSOCU54-CA-143837]
- National Science Foundation
Ask authors/readers for more resources
Chemotherapy is one of the primary treatment mechanisms for treating cancer. Current chemotherapy is systemically delivered and causes significant side effects; therefore the development of new chemotherapeutic agents or enhancing the effectiveness of current chemotherapeutic could prove vital to patients and cancer care. The purpose of this research was to develop a new conjugate composed of doxorubicin (chemotherapeutic) and inulin (polysaccharide chain) and evaluate its potential as a new therapeutic agent for cancer treatment. The synergistic effect of inulin conjugated to doxorubicin has allowed the same cytotoxic response to be maintained or improved at lower doses as compared to doxorubicin. Supporting results include cytotoxicity profiles, calf thymus DNA binding studies. confocal microscopy, and transport studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available